UA81453C2 - Pyrazolopyridine derivates - Google Patents

Pyrazolopyridine derivates

Info

Publication number: UA81453C2
Authority: UA; Ukraine
Prior art keywords: pyrazolopyridine; derivates; compounds; prodrugs; solvates
Prior art date: 2003-02-27

Application number

UAA200507292A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-27

Publication date

2008-01-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32930978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA81453(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-27 Priority claimed from ES200300640A external-priority patent/ES2214150B1/es

2003-03-14 Priority claimed from ES200300727A external-priority patent/ES2214976B1/es

2004-02-27 Application filed filed Critical

2008-01-10 Publication of UA81453C2 publication Critical patent/UA81453C2/xx

Links

AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
229940043355 kinase inhibitor Drugs 0.000 abstract 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

UAA200507292A 2003-02-27 2004-02-27 Pyrazolopyridine derivates UA81453C2 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
ES200300640A ES2214150B1 (es)	2003-02-27	2003-02-27	"nuevos derivados de pirazolopiridinas".
ES200300727A ES2214976B1 (es)	2003-03-14	2003-03-14	"nuevos derivados de pirazolopiridinas".
ES200302504		2003-10-27
PCT/EP2004/001974 WO2004076450A1 (en)	2003-02-27	2004-02-27	Pyrazolopyridine derivates

Publications (1)

Publication Number	Publication Date
UA81453C2 true UA81453C2 (en)	2008-01-10

Family

ID=32930978

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200507292A UA81453C2 (en)	2003-02-27	2004-02-27	Pyrazolopyridine derivates

Country Status (30)

Country	Link
US (3)	US7468376B2 (xx)
EP (1)	EP1611131B1 (xx)
JP (1)	JP4814783B2 (xx)
KR (1)	KR101312736B1 (xx)
AR (1)	AR043416A1 (xx)
AT (1)	ATE481402T1 (xx)
AU (1)	AU2004215644B2 (xx)
BR (1)	BRPI0407811A (xx)
CA (1)	CA2515197C (xx)
CL (1)	CL2004000398A1 (xx)
CY (1)	CY1111544T1 (xx)
DE (1)	DE602004029145D1 (xx)
DK (1)	DK1611131T3 (xx)
EC (2)	ECSP056041A (xx)
HK (1)	HK1085214A1 (xx)
HR (1)	HRP20050682B1 (xx)
IL (1)	IL196021A (xx)
IS (1)	IS2875B (xx)
MX (1)	MXPA05009069A (xx)
NO (1)	NO331917B1 (xx)
NZ (1)	NZ541836A (xx)
PE (1)	PE20050521A1 (xx)
PL (1)	PL378296A1 (xx)
PT (1)	PT1611131E (xx)
RS (1)	RS51768B (xx)
RU (1)	RU2359971C2 (xx)
SI (1)	SI1611131T1 (xx)
TW (1)	TWI325865B (xx)
UA (1)	UA81453C2 (xx)
WO (1)	WO2004076450A1 (xx)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004076450A1 (en) *	2003-02-27	2004-09-10	J. Uriach Y Compañia S.A.	Pyrazolopyridine derivates
ES2241496B1 (es) *	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
AR050188A1 (es) *	2004-08-03	2006-10-04	Uriach Y Compania S A J	Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
GB0427604D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
FR2880891B1 (fr) *	2005-01-19	2007-02-23	Aventis Pharma Sa	Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PE20061119A1 (es) *	2005-01-19	2006-11-27	Aventis Pharma Sa	PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
CN101208340B (zh) *	2005-06-27	2010-12-22	塞诺菲-安万特股份有限公司	作为β-肾上腺素能受体激酶1抑制剂的吡唑并吡啶衍生物
WO2007000043A2 (en) *	2005-06-27	2007-01-04	Ambrilia Biopharma Inc.	Pyrazolo[3,4-b]pyridin-2-yl]-benzoic acid derivatives as hiv integrase inhibitors
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
FR2889526B1 (fr)	2005-08-04	2012-02-17	Aventis Pharma Sa	7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1926734A1 (en)	2005-08-22	2008-06-04	Amgen Inc.	Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
JP2009506004A (ja) *	2005-08-25	2009-02-12	エフ．ホフマン−ラロシュアーゲー	ｐ３８ＭＡＰキナーゼ阻害剤としての縮合ピラゾール
BRPI0614884A2 (pt) *	2005-08-25	2011-04-19	Hoffmann La Roche	inibidores de p38 map cinase e métodos para uso dos mesmos
WO2007028129A1 (en) *	2005-09-02	2007-03-08	Pfizer Inc.	Hydroxy substituted 1h-imidazopyridines and methods
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
CN101365700A (zh)	2005-11-15	2009-02-11	沃泰克斯药物股份有限公司	可用作激酶抑制剂的氮杂吲唑
UY30796A1 (es) *	2006-12-15	2008-07-31	Bayer Schering Pharma Ag	3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos
EP1932845A1 (en) *	2006-12-15	2008-06-18	Bayer Schering Pharma Aktiengesellschaft	3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008104473A2 (en) *	2007-02-28	2008-09-04	F. Hoffmann-La Roche Ag	Pyrazolopyriidine derivatives and their use as kinase inhibitors
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8080546B2 (en)	2007-10-26	2011-12-20	Amgen Inc.	Pyrazolo-pyridinone derivatives and methods of use
EP2070929A1 (en)	2007-12-11	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009095752A1 (en) *	2008-01-29	2009-08-06	Glenmark Pharmaceuticals, S.A.	Fused pyrazole derivatives as cannabinoid receptor modulators
WO2010093595A1 (en)	2009-02-10	2010-08-19	E. I. Du Pont De Nemours And Company	Fungicidal 2-pyridones
WO2010111527A1 (en) *	2009-03-26	2010-09-30	Plexxikon, Inc.	Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
US20110034441A1 (en) *	2009-08-10	2011-02-10	Epitherix, Llc	Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
CN102595900B (zh)	2009-08-10	2015-07-15	萨穆梅德有限公司	Wnt信号传导途径的吲唑抑制剂及其治疗用途
WO2011019780A1 (en)	2009-08-11	2011-02-17	Bristol-Myers Squibb Company	Azaindazoles as btk kinase modulators and use thereof
FR2951172B1 (fr) *	2009-10-13	2014-09-26	Pf Medicament	Derives pyrazolopyridines en tant qu'agent anticancereux
EP3001903B1 (en)	2009-12-21	2017-10-25	Samumed, LLC	1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2012009510A1 (en)	2010-07-15	2012-01-19	Bristol-Myers Squibb Company	Azaindazole compounds
CN102617548A (zh) *	2011-01-31	2012-08-01	北京赛林泰医药技术有限公司	作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
TW201309634A (zh) *	2011-02-24	2013-03-01	Cephalon Inc	經取代之芳香硫化合物及其使用方法
LT2755483T (lt)	2011-09-14	2019-03-12	Samumed, Llc	Indazol-3-karboksamidai ir jų panaudojimas kaip wnt/b-katenino signalinio kelio slopiklių
PH12017500997A1 (en)	2012-04-04	2018-02-19	Samumed Llc	Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ724837A (en)	2012-05-04	2018-05-25	Samumed Llc	1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
RU2495039C1 (ru) *	2012-07-31	2013-10-10	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет"	МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-1,6-ДИФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-6-СТИРИЛ-1-ФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2014110086A2 (en)	2013-01-08	2014-07-17	Samumed, Llc	3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
CN104230922B (zh) *	2013-06-19	2016-12-28	中国科学院上海药物研究所	一类五元杂环并吡啶类化合物及其制备方法和用途
KR102378689B1 (ko) *	2013-10-17	2022-03-24	블루프린트 메디신즈 코포레이션	Kit에 관련된 장애를 치료하는데 유용한 조성물
WO2016040190A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en)	2014-09-08	2016-03-17	Samumed, Llc	3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2017023984A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024021A1 (en)	2015-08-03	2017-02-09	Samumed, Llc	3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023987A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10226453B2 (en)	2015-08-03	2019-03-12	Samumed, Llc	3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10231956B2 (en)	2015-08-03	2019-03-19	Samumed, Llc	3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10392383B2 (en)	2015-08-03	2019-08-27	Samumed, Llc	3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023980A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024010A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10329309B2 (en)	2015-08-03	2019-06-25	Samumed, Llc	3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10188634B2 (en)	2015-08-03	2019-01-29	Samumed, Llc	3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024026A1 (en)	2015-08-03	2017-02-09	Samumed, Llc	3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023975A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024025A1 (en)	2015-08-03	2017-02-09	Sunil Kumar Kc	3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023986A1 (en)	2015-08-03	2017-02-09	Samumed, Llc	3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10206909B2 (en)	2015-08-03	2019-02-19	Samumed, Llc	3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10195185B2 (en)	2015-08-03	2019-02-05	Samumed, Llc	3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
EP3370721A4 (en)	2015-11-06	2019-05-22	Samumed, LLC	TREATMENT OF OSTEOARTHRITIS
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US20170275662A1 (en) *	2016-03-22	2017-09-28	The Quaker Oats Company	Method and Apparatus for Controlled Hydrolysis
AR108325A1 (es)	2016-04-27	2018-08-08	Samumed Llc	Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US10072004B2 (en)	2016-06-01	2018-09-11	Samumed, Llc	Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
GB201611712D0 (en)	2016-07-02	2016-08-17	Hvivo Services Ltd	Methods and compounds for the treatment or prevention of severe or persistent influenza
EP3528808B1 (en)	2016-10-21	2021-10-06	BioSplice Therapeutics, Inc.	Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2018085865A1 (en)	2016-11-07	2018-05-11	Samumed, Llc	Single-dose, ready-to-use injectable formulations
WO2018183712A1 (en)	2017-03-31	2018-10-04	Blueprint Medicines Corporation	Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
JOP20190278A1 (ar)	2017-05-31	2019-11-28	Novartis Ag	مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt)	2017-10-05	2020-10-06	Fulcrum Therapeutics, Inc.	uso de inibidores p38 para reduzir a expressão de dux4
GB201721793D0 (en) *	2017-12-22	2018-02-07	Hvivo Services Ltd	Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
TWI845657B (zh)	2019-04-12	2024-06-21	美商纜圖藥品公司	(s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法
ES2980811T3 (es)	2019-04-12	2024-10-03	Blueprint Medicines Corp	Derivados de pirrolotriazina para el tratamiento de enfermedades mediadas por KIT y PDGFRA
WO2021067967A1 (en) *	2019-10-04	2021-04-08	University Of Kentucky Research Foundation	Preparation of pyrazolo[3,4-b]pyridines as antimalarials
WO2024150014A1 (en)	2023-01-13	2024-07-18	Poolbeg Pharma (UK) Limited	Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
WO2025093869A1 (en) *	2023-11-01	2025-05-08	Poolbeg Pharma (UK) Limited	P38 map kinase inhibitor for use in the treatment of inflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3403158A (en)	1966-03-11	1968-09-24	Upjohn Co	1h-pyrazolo[3, 4-b]pyridines
US4264603A (en)	1980-03-17	1981-04-28	Sterling Drug Inc.	5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridine-3-amines, their use as cardiotonics and their preparation
US4361568A (en)	1981-04-28	1982-11-30	Sterling Drug Inc.	5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridin-3-amines and their cardiotonic use
US4375467A (en)	1981-09-28	1983-03-01	Sterling Drug Inc.	5-(Pyridinyl)-1H-pyrazolo[3,4-b] pyridines and their cardiotonic use
CZ3696A3 (en)	1993-07-06	1997-06-11	Pfizer	Bicyclic tetrahydropyrazolepyridines per se and for treating diseases, and pharmaceutical compositions based thereon
CZ68199A3 (cs) *	1996-08-28	1999-11-17	Pfizer Inc.	6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
ES2281941T3 (es) *	1997-12-13	2007-10-01	Bristol-Myers Squibb Company	Uso de pirazolo(3,4-b)piridina como inhibidores de quinasa dependiente de ciclina.
US6559152B2 (en)	1998-10-13	2003-05-06	Dupont Pharmaceuticals Company	6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
AU767464B2 (en)	1998-11-03	2003-11-13	Glaxo Group Limited	Pyrazolopyridine derivatives as selective COX-2 inhibitors
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
JP2003512467A (ja)	1999-10-27	2003-04-02	ノバルティスアクチエンゲゼルシャフト	チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途
GB9929685D0 (en)	1999-12-15	2000-02-09	Merck Sharp & Dohme	Therapeutic agents
YU54202A (sh) *	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1278749B1 (en) *	2000-04-25	2005-01-26	Bristol-Myers Squibb Company	USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
CA2411084A1 (en)	2000-06-06	2001-12-13	Pfizer Products Inc.	Thiophene derivatives useful as anticancer agents
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2004509891A (ja)	2000-09-22	2004-04-02	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	抗糖尿病薬としてのピラゾロピリジンおよびピラゾロピリダジン
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
CA2437215A1 (en) *	2001-02-02	2002-08-15	Mitsubishi Pharma Corporation	Dihydropyrazolopyridine compounds and pharmaceutical use thereof
PT1368355E (pt)	2001-03-14	2006-09-29	Gruenenthal Gmbh	Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos
GB0124848D0 (en) *	2001-10-16	2001-12-05	Celltech R&D Ltd	Chemical compounds
AU2003245700A1 (en) *	2002-02-12	2003-09-04	Glaxo Group Limited	Pyrazolopyridine derivatives
MXPA05001688A (es)	2002-08-12	2005-04-19	Sugen Inc	3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
UA81790C2 (uk)	2002-12-19	2008-02-11	Фармация Италия С.П.А.	Заміщені піролопіразольні похідні як інгібітори кінази
WO2004076450A1 (en) *	2003-02-27	2004-09-10	J. Uriach Y Compañia S.A.	Pyrazolopyridine derivates
EP1620095A4 (en)	2003-04-24	2009-04-01	Merck & Co Inc	INHIBITORS OF AKT ACTIVITY
AR044129A1 (es)	2003-05-06	2005-08-24	Altana Pharma Ag	Compuestos intermedios de imidazopiridina. proceso de preparacion.
EP1675858A2 (en)	2003-09-03	2006-07-05	Neurogen Corporation	5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds

2004
- 2004-02-27 WO PCT/EP2004/001974 patent/WO2004076450A1/en active Application Filing
- 2004-02-27 JP JP2006501971A patent/JP4814783B2/ja not_active Expired - Fee Related
- 2004-02-27 KR KR1020057016025A patent/KR101312736B1/ko not_active Expired - Fee Related
- 2004-02-27 AR ARP040100616A patent/AR043416A1/es not_active Application Discontinuation
- 2004-02-27 CA CA2515197A patent/CA2515197C/en not_active Expired - Fee Related
- 2004-02-27 PT PT04715268T patent/PT1611131E/pt unknown
- 2004-02-27 US US10/547,232 patent/US7468376B2/en not_active Expired - Fee Related
- 2004-02-27 BR BRPI0407811-0A patent/BRPI0407811A/pt not_active IP Right Cessation
- 2004-02-27 MX MXPA05009069A patent/MXPA05009069A/es active IP Right Grant
- 2004-02-27 NZ NZ541836A patent/NZ541836A/en not_active IP Right Cessation
- 2004-02-27 PL PL378296A patent/PL378296A1/pl unknown
- 2004-02-27 DK DK04715268.1T patent/DK1611131T3/da active
- 2004-02-27 TW TW093105205A patent/TWI325865B/zh not_active IP Right Cessation
- 2004-02-27 PE PE2004000211A patent/PE20050521A1/es not_active Application Discontinuation
- 2004-02-27 AU AU2004215644A patent/AU2004215644B2/en not_active Ceased
- 2004-02-27 UA UAA200507292A patent/UA81453C2/xx unknown
- 2004-02-27 CL CL200400398A patent/CL2004000398A1/es unknown
- 2004-02-27 RS YU20050609A patent/RS51768B/sr unknown
- 2004-02-27 EP EP04715268A patent/EP1611131B1/en not_active Expired - Lifetime
- 2004-02-27 DE DE602004029145T patent/DE602004029145D1/de not_active Expired - Lifetime
- 2004-02-27 SI SI200431568T patent/SI1611131T1/sl unknown
- 2004-02-27 AT AT04715268T patent/ATE481402T1/de active
- 2004-02-27 RU RU2005130020/04A patent/RU2359971C2/ru active IP Right Revival
2005
- 2005-07-14 IS IS7939A patent/IS2875B/is unknown
- 2005-07-27 NO NO20053647A patent/NO331917B1/no not_active IP Right Cessation
- 2005-07-29 HR HRP20050682AA patent/HRP20050682B1/hr not_active IP Right Cessation
- 2005-09-27 EC EC2005006041A patent/ECSP056041A/es unknown
2006
- 2006-06-24 HK HK06107182.7A patent/HK1085214A1/xx not_active IP Right Cessation
2008
- 2008-09-08 US US12/206,289 patent/US8536194B2/en active Active
- 2008-12-18 IL IL196021A patent/IL196021A/en active IP Right Grant
2009
- 2009-07-29 US US12/511,469 patent/US20090286983A1/en not_active Abandoned
2010
- 2010-12-10 CY CY20101101149T patent/CY1111544T1/el unknown
2012
- 2012-03-30 EC ECSP12006041 patent/ECSP12006041A/es unknown

Also Published As

Publication number	Publication date
KR101312736B1 (ko)	2013-09-27
ATE481402T1 (de)	2010-10-15
US20090005377A1 (en)	2009-01-01
AU2004215644A1 (en)	2004-09-10
AR043416A1 (es)	2005-07-27
US20090286983A1 (en)	2009-11-19
SI1611131T1 (sl)	2011-03-31
IS2875B (is)	2014-04-15
US7468376B2 (en)	2008-12-23
IS7939A (is)	2005-07-14
BRPI0407811A (pt)	2006-02-14
DE602004029145D1 (de)	2010-10-28
IL196021A0 (en)	2009-02-11
EP1611131A1 (en)	2006-01-04
CA2515197A1 (en)	2004-09-10
RU2005130020A (ru)	2006-07-10
DK1611131T3 (da)	2011-01-17
JP2006519205A (ja)	2006-08-24
RS51768B (sr)	2011-12-31
IL196021A (en)	2011-10-31
ECSP12006041A (es)	2012-12-28
NO331917B1 (no)	2012-04-30
AU2004215644B2 (en)	2010-09-02
WO2004076450A8 (en)	2005-09-01
HRP20050682A2 (en)	2006-05-31
EP1611131B1 (en)	2010-09-15
NO20053647D0 (no)	2005-07-27
KR20060002782A (ko)	2006-01-09
HK1085214A1 (en)	2006-09-29
US8536194B2 (en)	2013-09-17
CA2515197C (en)	2011-10-18
HRP20050682B1 (hr)	2014-09-12
PL378296A1 (pl)	2006-03-20
NZ541836A (en)	2008-12-24
TW200504061A (en)	2005-02-01
ECSP056041A (es)	2006-01-27
NO20053647L (no)	2005-10-18
CL2004000398A1 (es)	2005-03-18
TWI325865B (en)	2010-06-11
RU2359971C2 (ru)	2009-06-27
PE20050521A1 (es)	2005-09-11
CY1111544T1 (el)	2015-08-05
RS20050609A (xx)	2007-12-31
WO2004076450A1 (en)	2004-09-10
PT1611131E (pt)	2010-12-20
MXPA05009069A (es)	2005-10-19
US20060167040A1 (en)	2006-07-27
JP4814783B2 (ja)	2011-11-16

Publication	Publication Date	Title
UA81453C2 (en)	2008-01-10	Pyrazolopyridine derivates
TW200618800A (en)	2006-06-16	Heterocyclic compounds
TW200728277A (en)	2007-08-01	Bicyclic derivatives as P38 inhibitors
GEP20074236B (en)	2007-11-12	Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
RS92004A (xx)	2006-12-15	Pirolo-triazin anilinska jedinjenja, korisna kao inhibitori kinaze
PL372926A1 (en)	2005-08-08	Piperidine-pyridazones and phthalazones as pde4 inhibitors
IL163781A0 (en)	2005-12-18	Purine derivatives as kinase inhibitors
MX2009010595A (es)	2009-10-22	Derivados de pirrolopirimidina.
MX2009007302A (es)	2009-07-15	Derivados de purina.
MX2008002104A (es)	2008-04-17	Derivados de 1-acildihidropirazol.
WO2007000340A3 (en)	2007-03-29	Bicyclic derivatives as p38 kinase inhibitors
MY145281A (en)	2012-01-13	Novel compounds
IL173810A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
GB0308201D0 (en)	2003-05-14	Novel compounds
IS7507A (is)	2004-10-15	Ný efnasambönd
MXPA05009151A (es)	2005-10-20	Inhibidores de cinasa heterociclica.
AP2002002466A0 (en)	2002-06-30	3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
NO20082105L (no)	2008-07-31	Pyrazoloisokinolinderivater
IL173895A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2007000337A8 (en)	2007-04-19	Bicyclic derivatives as p38 kinase inhibitors
MY154498A (en)	2015-06-30	Pyrazolone derivatives as pde4 inhibitors
MXPA05006957A (es)	2005-09-30	Nuevos derivados de fosforamida.
TW200615274A (en)	2006-05-16	Chemical compounds